Ruthann M. Giusti

FDA Drug Approval Summary: Panitumumab (Vectibix™)

Ruthann M. Giusti, Kaushikkumar A. Shastri, Martin H. Cohen et al. · The Oncologist · 2007 · 216 citations

Medicine, Oncology, Pharmacology +14

Failure of Ciprofloxacin to Eradicate Convalescent Fecal Excretion after Acute Salmonellosis: Experience during an Outbreak in Health Care Workers

Marguerite A. Neill, Steven M. Opal, Judith S. Heelan et al. · Annals of Internal Medicine · 1991 · 137 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

Ruthann M. Giusti, Kaushikkumar A. Shastri, Anne M. Pilaro et al. · Clinical Cancer Research · 2008 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17

Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma.

Ruthann M. Giusti, Elizabeth M. Maloney, B Hanchard et al. · PubMed · 1996 · 61 citations

Life Sciences, Immunology, Pathobiology +14

Mutational analysis of the<i>BRCA1</i>-interacting genes<i>ZNF350/ZBRK1</i>and<i>BRIP1</i>/<i>BACH1</i>among<i>BRCA1</i>and<i>BRCA2</i>-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals

Joni L. Rutter, Amelia M. Smith, Michael R. Dávila et al. · Human Mutation · 2003 · 55 citations

Medicine, Genetics, Molecular Genetics +14